Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Sterling Capital Management LLC

Sterling Capital Management LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 601.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,087 shares of the biopharmaceutical company's stock after buying an additional 15,507 shares during the period. Sterling Capital Management LLC's holdings in Alnylam Pharmaceuticals were worth $4,256,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ALNY. Treasurer of the State of North Carolina boosted its stake in shares of Alnylam Pharmaceuticals by 2.7% in the fourth quarter. Treasurer of the State of North Carolina now owns 86,915 shares of the biopharmaceutical company's stock valued at $20,452,000 after buying an additional 2,310 shares in the last quarter. Winslow Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Winslow Capital Management LLC now owns 1,020,567 shares of the biopharmaceutical company's stock worth $240,150,000 after purchasing an additional 58,960 shares in the last quarter. Greenland Capital Management LP grew its stake in shares of Alnylam Pharmaceuticals by 81.2% during the 4th quarter. Greenland Capital Management LP now owns 2,000 shares of the biopharmaceutical company's stock worth $471,000 after purchasing an additional 896 shares during the period. FIL Ltd grew its stake in shares of Alnylam Pharmaceuticals by 48.8% during the 4th quarter. FIL Ltd now owns 22,066 shares of the biopharmaceutical company's stock worth $5,192,000 after purchasing an additional 7,236 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $682,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company's stock, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Up 1.8 %

Shares of ALNY stock traded up $4.06 on Friday, reaching $234.56. 601,349 shares of the stock were exchanged, compared to its average volume of 870,111. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The stock has a market cap of $30.51 billion, a P/E ratio of -108.09 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a 50 day moving average of $249.82 and a two-hundred day moving average of $257.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ALNY. Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Needham & Company LLC reissued a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.